European Union - English - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Israel - English - Ministry of Health

medison pharma ltd - fenfluramine as hydrochloride - oral solution - fenfluramine as hydrochloride 2.2 mg / 1 ml - fenfluramine - fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - fenfluramine hydrochloride 20mg - tablet - 20 mg - active: fenfluramine hydrochloride 20mg

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - fenfluramine hydrochloride 40mg - tablet - 40 mg - active: fenfluramine hydrochloride 40mg

New Zealand - English - Medsafe (Medicines Safety Authority)

servier laboratories nz ltd - fenfluramine hydrochloride 60mg - modified release capsule - 60 mg - active: fenfluramine hydrochloride 60mg

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 49.7 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350; brilliant scarlet 4r aluminium lake - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 37.275 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 18.6375 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; iron oxide yellow; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350 - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - phentermine hydrochloride, quantity: 49.776 mg - capsule, modified release - excipient ingredients: liquid paraffin; lactose monohydrate; magnesium stearate; iron oxide black; sodium polystyrene sulfonate; sunset yellow fcf; titanium dioxide; gelatin; erythrosine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - phentermine hydrochloride, quantity: 37.332 mg - capsule, modified release - excipient ingredients: gelatin; liquid paraffin; magnesium stearate; titanium dioxide; sodium polystyrene sulfonate; iron oxide red; lactose monohydrate; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.